Abstract:OBJECTIVE:To evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension. METHOD:This is a randomized, double-blind, double-dummy, active-controlled, parallel, multi-center study. After a 2-week placebo run-in period, a total of 287 eligible subjects were randomized at 1:1 ratio to receive olmesartan medoxomil 20 mg or losartan potassium 50 mg, once daily for 8 weeks. The blood pressure was assessed after 4 weeks treatment. If the subject's seating diastolic blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the initial dosage remained unchanged and the treatment continued until completion of the study. RESULTS:(1) The mean trough reduction in SeDBP from baseline in olmesartan group was significantly greater than that in losartan group after 4 weeks (11.72 mm Hg vs 9.23 mm Hg, P=0.004) and 8 weeks treatment (12.94 mm Hg vs 11.01 mm Hg, P=0.035). (2) The number and percentage of responders in olmesartan group (81, 65.3%) were statistically higher than those (68, 52.7%) in losartan group (P=0.028) after 4 weeks treatment and were similar between the two groups after 8 weeks treatment (P>0.05). (3) Individual and overall trough/peak ratios of DBP and SBP in 24-hour ambulatory blood pressure monitoring were higher in olmesartan group than losartan group. The hypotensive effect of olmesartan was more durable than losartan at 24 hour interval. (4) The incidence of study drug-related adverse events (AEs) in olmesartan group (10.5%) was similar as that in losartan group (13.9%, P>0.05). Most of these AEs were mild and transient. CONCLUSION:This study shows that olmesartan medoxomil, at oral dose of 20 mg-40 mg once daily was effective and safe for hypertension treatment and the hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily).

Summary of Synthesis Methods of Olmesartan Medoxomil and Key Intermediates

Recent Advances in the Synthesis and Analysis of Atorvastatin and Its Intermediates

Highly Efficient and Practical Synthesis of the Key Intermediate of Telmisartan

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

Synthesis and characterization of related substances of Azilsartan Kamedoxomil

Synthesis of 6-Fluoro-3,4-dihydro-2h-1-benzopyran-2-carboxylic Acid

ChemInform Abstract: An Improved Synthesis of a β‐Blocker Celiprolol Hydrochloride (X).

Identification, Synthesis, and Comprehension of an Imidazole N-3 Regioisomeric Impurity of Olmesartan Medoxomil Key Intermediate

Synthesis of 3-Aminopyrrolidine and its N-alkylating Derivatives

Synthesis of N-Methyl-4-aminobenzyl Sulfonamide

Efficient Synthesis of Valsartan, A Nonpeptide Angiotensin Ii Receptor Antagonist

Commercial Synthesis of Azilsartan Kamedoxomil: An Angiotensin II Receptor Blocker

Improved Process for Azilsartan Medoxomil: A New Angiotensin Receptor Blocker

An alternative synthesis of Azilsartan: an angiotensin II receptor blocker

The Synthetic Technology of Ranolazine

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Synthesis of 2,3-Dihydro-1,4-benzoxathiine Derivatives

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Synthesis of a New Antihyperlipidaemic Agent-Simvastatin

Conversion of Olmesartan to Olmesartan Medoxomil, A Prodrug that Improves Intestinal Absorption, Confers Substrate Recognition by OATP2B1